Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Artemis II shares new lunar images while more than halfway to the moon - 2Vote In favor of Your Favored IT Administration
- 3The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- 4Astonishing interstellar comet captured in new images by NASA Mars missions
- 5Instructions to Pick the Right Tires for Your Slam 1500.
- South Korea president says Iran war shows the need to ditch ‘extremely risky’ fossil fuels
- Fact Check: Some Bridge Photos Circulating Do NOT Show The Hongqi Bridge That Collapsed In Southwest China Nov. 11, 2025
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- No respite for German economy as experts slash forecast over Iran war
- Archaeologists uncover details about the Hjortspring boat's origins
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
